A Phase 3 interventional study of Bimekizumab and Placebo in Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis and Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 77 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 5th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 435 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 210 across the 14 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 5 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
18 studies in Arthritis, Psoriatic by UCB S.A.: 2 open now, 3 under way, 1 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 18 studies in Arthritis, Psoriatic by UCB S.A., this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2018, is one of 9 in phase 3, and was the 9th registered.
UCB S.A.’s Arthritis, Psoriatic studies by the year they started, since 2010.
1 of the studies testing bimekizumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 18 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
Drug: Bimekizumab · Other: Placebo
Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
Other: Placebo
Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
Drug: Bimekizumab
Bimekizumab will be provided at pre-specified time intervals.
Also known as: UCB4940
Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Also known as: PBO
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
Time frame: At Week 16
Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-Inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
Time frame: At Week 16
Percentage of Participants With a PASI100 Response at Week 16
A PASI100 responder was defined as a participant that achieved 100% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
Time frame: At Week 16
Percentage of Participants With a IGA Clear Response at Week 16
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear with at least \>= 2 category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
Time frame: At Week 16
Percentage of Participants With a PASI75 Response at Week 4
A PASI75 responder was defined as a participant that achieved 75% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at a given week were counted as nonresponders.
Time frame: At Week 4
Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16
As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.
Time frame: At Week 16
Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16
A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.
Time frame: At Week 16
Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16
As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.
Time frame: At Week 16
Percentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline
Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.
Time frame: At Week 16
Percentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders
A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Study participants with missing score at Week 56 or who met the criterion for relapse were counted as nonresponders (NRI).
Time frame: At Week 56
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline to end of Initial Treatment Period (up to Week 16)
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From end of Initial Treatment Period (Week 16) until the Safety Follow-Up (up to 56 weeks duration)
Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Escape Baseline (Week 0) until Safety Follow-Up (up to 28 weeks duration)
The study started to enroll patients in February 2018 and concluded in January 2020.
| Milestone | Placebo | Bimekizumab 320 mg Q4W | Placebo/Placebo | Bimekizumab 320 mg Q4W/Placebo | Bimekizumab 320 mg Q4W/Q8W | Bimekizumab 320 mg Q4W/Q4W | Placebo Escape | Bimekizumab 320 mg Q4W Escape | Bimekizumab 320 mg Q4W/ Placebo Escape | Bimekizumab 320 mg Q4W/Q8W Escape | Bimekizumab 320 mg Q4W/Q4W Escape |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 86 | 349 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 82 | 340 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Bimekizumab 320 mg Q4W | Placebo/Placebo | Bimekizumab 320 mg Q4W/Placebo | Bimekizumab 320 mg Q4W/Q8W | Bimekizumab 320 mg Q4W/Q4W | Placebo Escape | Bimekizumab 320 mg Q4W Escape | Bimekizumab 320 mg Q4W/ Placebo Escape | Bimekizumab 320 mg Q4W/Q8W Escape | Bimekizumab 320 mg Q4W/Q4W Escape |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 82 | 340 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received escape treatment | 81 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 1 | 311 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 81 | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pasi90 non-response at week 16 | 81 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Incorrect escapers | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Bimekizumab 320 mg Q4W | Placebo/Placebo | Bimekizumab 320 mg Q4W/Placebo | Bimekizumab 320 mg Q4W/Q8W | Bimekizumab 320 mg Q4W/Q4W | Placebo Escape | Bimekizumab 320 mg Q4W Escape | Bimekizumab 320 mg Q4W/ Placebo Escape | Bimekizumab 320 mg Q4W/Q8W Escape | Bimekizumab 320 mg Q4W/Q4W Escape |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 1 | 105 | 100 | 106 | 0 | 0 | 0 | 0 | 0 |
| Received escape treatment | 0 | 0 | 0 | 67 | 4 | 7 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 1 | 33 | 93 | 94 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 72 | 7 | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Relapse at week 20 or later | 0 | 0 | 0 | 67 | 4 | 7 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Bimekizumab 320 mg Q4W | Placebo/Placebo | Bimekizumab 320 mg Q4W/Placebo | Bimekizumab 320 mg Q4W/Q8W | Bimekizumab 320 mg Q4W/Q4W | Placebo Escape | Bimekizumab 320 mg Q4W Escape | Bimekizumab 320 mg Q4W/ Placebo Escape | Bimekizumab 320 mg Q4W/Q8W Escape | Bimekizumab 320 mg Q4W/Q4W Escape |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 23 | 67 | 4 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 22 | 66 | 4 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 | 1.2 | 90.8 |
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-Inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear or Almost Clear with at least a 2-category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With an Investigator's Global Assessment (IGA) Response at Week 16 | 1.2 | 92.6 |
A PASI100 responder was defined as a participant that achieved 100% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a PASI100 Response at Week 16 | 1.2 | 68.2 |
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response was defined as Clear with at least \>= 2 category improvement relative to Baseline. Study participants with missing score at Week 16 were counted as nonresponders (NRI).
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a IGA Clear Response at Week 16 | 1.2 | 69.6 |
A PASI75 responder was defined as a participant that achieved 75% reduction from Baseline in the PASI score. Body divided into 4 areas: head/arms/trunk to groin/legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear)-4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0-6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The min possible PASI score is 0=no disease, the max score is 72=maximal disease. Study participants with missing score at a given week were counted as nonresponders.
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a PASI75 Response at Week 4 | 1.2 | 75.9 |
As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD pain item was assessed daily on a numeric rating scale (NRS) from 0 (no pain) to 10 (very severe pain). PSD score for pain at a given visit was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in pain score higher than the prespecified 1.98 response threshold at Week 16. The endpoint was characterized as percentage of participants with PSD pain response.
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a Patient Symptom Diary Response for Pain at Week 16 | 9.0 | 78.8 |
A PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD itch item was assessed daily on a NRS from 0 (no itch) to 10 (very severe itch). PSD score for itch was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in itch score higher than the prespecified 2.39 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD itch response.
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a Patient Symptom Diary Response for Itch at Week 16 | 5.6 | 75.5 |
As PRO measure, the PSD (further published as P-SIM) was used to assess key symptoms relevant to patients with moderate to severe plaque psoriasis. Site staff trained participants on the use of the electronic device used to collect ePRO diary data at Screening, device was then dispensed to the participant for home use until Week 16 Visit. The ePRO diary was completed on daily basis from Screening to Week 16 Visit. PSD scaling item was assessed daily on a NRS from 0 (no scaling) to 10 (very severe scaling). PSD score for scaling was an average of daily values over the week prior to the visit. The response was defined as an improvement (decrease) in scaling score higher than the prespecified 2.86 response threshold at Week 16. The endpoint was characterized as percentage of participants with a PSD scaling response.
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With a Patient Symptom Diary Response for Scaling at Week 16 | 5.7 | 78.0 |
Only participants with scalp involvement at Baseline completed the scalp IGA. Participants with scalp involvement at Baseline were defined as those with a scalp IGA score \>0 at Baseline. Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe). Scalp IGA 0/1 response at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.
| percentage of participants | Placebo (RS) | Bimekizumab 320 mg Q4W (RS) |
|---|---|---|
| Percentage of Participants With Scalp IGA Response (Clear or Almost Clear) at Week 16 for Participants With Scalp Psoriasis (PSO) at Baseline | 6.8 | 92.3 |
A PASI90 responder was defined as a participant that achieved 90% reduction from Baseline in the PASI score. Study participants with missing score at Week 56 or who met the criterion for relapse were counted as nonresponders (NRI).
| percentage of participants | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W+Q4W/Q4W (WK16ResS) |
|---|---|---|---|---|
| Percentage of Participants With a PASI90 Response at Week 56 Among Week 16 PASI90 Responders | 16.2 | 91.0 | 86.8 | 88.8 |
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period | 177.38 (123.55 to 246.69) | 323.61 (281.60 to 370.11) |
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|
| Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period | 7.66 (0.93 to 27.68) | 5.59 (2.05 to 12.17) |
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo (SS) | Bimekizumab 320 mg Q4W (SS) |
|---|---|---|
| Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Initial Treatment Period | 0 (NA to NA) | 2.78 (0.57 to 8.12) |
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) |
|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period | 144.37 (3.66 to 804.36) | 242.11 (189.44 to 304.90) | 224.87 (177.46 to 281.05) | 208.88 (165.11 to 260.69) |
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) |
|---|---|---|---|---|
| Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period | 0 (NA to NA) | 7.20 (1.96 to 18.43) | 4.04 (0.83 to 11.80) | 6.64 (2.16 to 15.50) |
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) |
|---|---|---|---|---|
| Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Randomized-Withdrawal Period | 0 (NA to NA) | 5.33 (1.10 to 15.58) | 2.69 (0.33 to 9.71) | 0 (NA to NA) |
The number of TEAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the adverse event (AE) being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo Escape (ESS) | Bimekizumab 320 mg Q4W Escape (ESS) | Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | Bimekizumab 320 mg Q4W/Q4W Escape (ESS) |
|---|---|---|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment | 235.86 (164.29 to 328.03) | 287.19 (143.36 to 513.86) | 180.89 (115.90 to 269.15) | 491.37 (101.33 to 1435.98) | 349.52 (95.23 to 894.91) |
The number of SAEs adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo Escape (ESS) | Bimekizumab 320 mg Q4W Escape (ESS) | Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | Bimekizumab 320 mg Q4W/Q4W Escape (ESS) |
|---|---|---|---|---|---|
| Number of Serious Adverse Events (SAEs) Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment | 5.24 (0.13 to 29.22) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
The number of TEAEs leading to discontinuation adjusted by duration of exposure to study treatment was scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Placebo Escape (ESS) | Bimekizumab 320 mg Q4W Escape (ESS) | Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | Bimekizumab 320 mg Q4W/Q4W Escape (ESS) |
|---|---|---|---|---|---|
| Number of TEAEs Leading to Withdrawal Adjusted by Duration of Participant Exposure to Study Treatment During the Escape Treatment | 0 (NA to NA) | 18.77 (0.48 to 104.58) | 0 (NA to NA) | 0 (NA to NA) | 0 (NA to NA) |
Collected over Adverse events were collected from Baseline (Week 0) until Safety Follow-Up Visit (up to 80 weeks duration). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (SS) | 0/86 (0%) | 2/86 (2.3%) | 15/86 (17.4%) |
| Bimekizumab 320 mg Q4W (SS) | 0/349 (0%) | 6/349 (1.7%) | 66/349 (18.9%) |
| Placebo/Placebo (WK16ResS) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | 0/105 (0%) | 4/105 (3.8%) | 34/105 (32.4%) |
| Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | 0/100 (0%) | 3/100 (3%) | 40/100 (40%) |
| Bimekizumab 320 mg Q4W/Q4W (WK16ResS) | 0/106 (0%) | 5/106 (4.7%) | 34/106 (32.1%) |
| Placebo Escape (ESS) | 0/81 (0%) | 1/81 (1.2%) | 8/81 (9.9%) |
| Bimekizumab 320 mg Q4W Escape (ESS) | 0/23 (0%) | 0/23 (0%) | 5/23 (21.7%) |
| Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | 0/67 (0%) | 0/67 (0%) | 11/67 (16.4%) |
| Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Bimekizumab 320 mg Q4W/Q4W Escape (ESS) | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Event | Placebo (SS) | Bimekizumab 320 mg Q4W (SS) | Placebo/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) | Placebo Escape (ESS) | Bimekizumab 320 mg Q4W Escape (ESS) | Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | Bimekizumab 320 mg Q4W/Q4W Escape (ESS) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/86 | 0/349 | 0/1 | 0/105 | 2/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Ischaemic cardiomyopathyCardiac disorders | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 1/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Coronary artery diseaseCardiac disorders | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 1/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 1/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 1/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| SyncopeNervous system disorders | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 1/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Myocardial infarctionCardiac disorders | 1/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Mitral valve prolapseCardiac disorders | 1/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Acute myocardial infarctionCardiac disorders | 0/86 | 0/349 | 0/1 | 0/105 | 1/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Retinal detachmentEye disorders | 0/86 | 1/349 | 0/1 | 1/105 | 0/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 0/7 |
| Event | Placebo (SS) | Bimekizumab 320 mg Q4W (SS) | Placebo/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Placebo (WK16ResS) | Bimekizumab 320 mg Q4W/Q8W (WK16ResS) | Bimekizumab 320 mg Q4W/Q4W (WK16ResS) | Placebo Escape (ESS) | Bimekizumab 320 mg Q4W Escape (ESS) | Bimekizumab 320 mg Q4W/ Placebo Escape (ESS) | Bimekizumab 320 mg Q4W/Q8W Escape (ESS) | Bimekizumab 320 mg Q4W/Q4W Escape (ESS) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/86 | 14/349 | 1/1 | 5/105 | 8/100 | 12/106 | 3/81 | 1/23 | 2/67 | 0/4 | 1/7 |
| Dental cariesGastrointestinal disorders | 1/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 0/81 | 0/23 | 0/67 | 1/4 | 0/7 |
| ImpetigoInfections and infestations | 1/86 | 2/349 | 0/1 | 1/105 | 0/100 | 1/106 | 0/81 | 0/23 | 0/67 | 1/4 | 0/7 |
| Rib fractureInjury, poisoning and procedural complications | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 1/106 | 0/81 | 0/23 | 0/67 | 1/4 | 0/7 |
| NasopharyngitisInfections and infestations | 4/86 | 23/349 | 0/1 | 20/105 | 23/100 | 11/106 | 1/81 | 1/23 | 2/67 | 0/4 | 0/7 |
| NeutropeniaBlood and lymphatic system disorders | 0/86 | 2/349 | 0/1 | 0/105 | 1/100 | 0/106 | 0/81 | 1/23 | 0/67 | 0/4 | 1/7 |
| Tinea pedisInfections and infestations | 0/86 | 4/349 | 0/1 | 0/105 | 0/100 | 1/106 | 0/81 | 0/23 | 0/67 | 0/4 | 1/7 |
| Body tineaInfections and infestations | 0/86 | 1/349 | 0/1 | 0/105 | 1/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 1/7 |
| Tinea capitisInfections and infestations | 0/86 | 0/349 | 0/1 | 0/105 | 0/100 | 0/106 | 0/81 | 0/23 | 0/67 | 0/4 | 1/7 |
| PsoriasisSkin and subcutaneous tissue disorders | 4/86 | 1/349 | 0/1 | 3/105 | 0/100 | 1/106 | 0/81 | 1/23 | 0/67 | 0/4 | 1/7 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all randomized study participants.
| Age, Categorical(Participants) | Placebo | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|
| <=18 years | 2 | 1 | 3 |
| Between 18 and 65 years | 80 | 327 | 407 |
| >=65 years | 4 | 21 | 25 |
| Age, Continuous(years) | Placebo | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|
| Mean | 43.5 ± 13.1 | 44.5 ± 12.9 | 44.3 ± 12.9 |
| Sex: Female, Male(Participants) | Placebo | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|
| Female | 28 | 94 | 122 |
| Male | 58 | 255 | 313 |
| Race/Ethnicity, Customized(Participants) | Placebo | Bimekizumab 320 mg Q4W | Total Title |
|---|---|---|---|
| Asian | 5 | 13 | 18 |
| Black | 0 | 6 | 6 |
| Native Hawaiian or other Pacific Islander | 0 | 2 | 2 |
| White | 79 | 324 | 403 |
| Other/mixed | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2018 to primary completion in Dec 2018, 10 months.
Results were first posted in Mar 2022, 3 years 2 months after primary completion. A results delay was requested in Jan 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 10 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab